The Bombay Burmah Trading Corporation (501425) Q4 96/97 earnings summary
Event summary combining transcript, slides, and related documents.
Q4 96/97 earnings summary
22 Oct, 2026Executive summary
FY ended 31 Mar 1997: profit before tax rose to Rs. 956.92 lakhs from Rs. 842.95 lakhs; profit after tax reached Rs. 706.92 lakhs from Rs. 602.95 lakhs.
Sales were Rs. 9,967.34 lakhs versus Rs. 10,124.50 lakhs; reported total income was Rs. 11,452.54 lakhs versus Rs. 11,155.67 lakhs.
Financial highlights
Operating and other expenses were Rs. 4,243.33 lakhs, employee costs Rs. 2,789.30 lakhs, interest Rs. 777.02 lakhs and depreciation Rs. 295.63 lakhs.
Other income was Rs. 1,101.30 lakhs; it included Rs. 223.83 lakhs from an earlier-year excise provision reversal and Rs. 281.86 lakhs loss on sale of investments was expensed.
Operating cash flow was negative Rs. 529.78 lakhs; investing cash flow was negative Rs. 849.47 lakhs and financing cash flow was positive Rs. 438.99 lakhs.
Outlook and guidance
BCL Springs was expected to further improve performance in FY 1997-98 following higher capacity; the completed Afcoset weighing-scales project was expected to begin sales in June 1997.
Commercial production of pre-laminated particle boards began after trial production and test marketing; new facility was expected to support the Central India Board Products Division.
Tea prices firmed in the final quarter and that trend continued; coffee prices rose significantly after year-end, particularly Arabica.
Latest events from The Bombay Burmah Trading Corporation
- Profit rose on stronger plantation realisations; new manufacturing lines launched.501425
Q4 97/98 - Labor disruption and particle-board losses drove a steep FY99 profit decline.501425
Q4 98/99 - Labour disruption, cost inflation and tea-price pressure drove a sharp loss.501425
Q4 99/00 - Commodity-price pressure and estate disruptions drove another loss; the dividend was skipped.501425
Q4 01/02 - Profit returned as operational gains offset weak tea and coffee markets.501425
Q4 02/03 - Profit rebounded as lower financing costs and industrial gains offset plantation pressures.501425
Q4 03/04 - Higher profits and associate earnings met drought, cost and currency pressures.501425
Q4 04/05 - FY06 profit rose amid cost pressure, with expansion and healthcare poised to drive growth.501425
Q4 05/06 - Standalone earnings improved; acquisitions and new capacity set up growth, with VRS costs deferred to FY08.501425
Q4 06/07